pfizer glp-1 news cofepris 🚀Could monthly be the next major advance in obesity treatment? By Pfizer discontinues oral GLP-1 receptor

Patients must combine medication with healthy lifestyle choices

Weight loss through lifestyle interventions clearly improves metabolic factors associated with obesity as well as conditions coexisting with obesity, warranting its use as a first-line treatment

TYPE B OR IDIOSYNCRATIC ADVERSE DRUG REACTIONS : Paracetamol: An Example of a Drug That Causes Toxicity Through the Formation of a Chemically Reactive Intermediate PARACETAMOL: AN EXAMPLE OF A DRUG THAT CAUSES TOXICITY THROUGH THE FORMATION OF A CHEMICALLY REACTIVE INTERMEDIATE For many drugs that undergo metabolism, CRM will be formed irrespective of the dose of the drug (Pirmohamed, Madden and Park, 1996)

Hyperammonaemia in organic acidurias can be life-threatening [3]